Search Results

The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to counteract past tolerability issues.

DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.

Genentech is letting go of 118 employees in South San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.

Anova Enterprises, Inc. has collaborated with University of California at San Francisco, University of California at San Diego, the University of Southern California and Denovo Biopharma to manage a newly awarded $11.8M California Institute for Regenerative Medicine grant to support the development of DB107 in patients with newly diagnosed high-grade glioma.

IASO Biotechnology (“IASO Bio”) today announces that the investigational new drug (IND) application for RD118, an independently developed, fully human GPRC5D-targeting chimeric antigen receptor T-cell (CAR-T) therapy, has been approved by the National Medical Products Administration (NMPA) for treatment of relapsed/refractory multiple myeloma (RRMM).

Denovo Biopharma LLC (Denovo) today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $11.8M grant for further development of DB107, Denovo’s DGM7™ biomarker–guided late–stage gene therapy, for high–grade glioma (HGG) including glioblastoma (GBM), a malignant brain cancer.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.

Zenas BioPharma closed on a Series B financing round worth $118 million, which it will use to advance its autoimmune candidate obexelimab into a global Phase III trial later this year.